StemCells (STEM) Bullish Stance Reiterated at Maxim Group on Positive Spine Paralysis Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
StemCells (STEM) Provided Data on Phase I/II Trial in Spinal Cord Injury
May 19, 2014 8:10 AM EDTStemCells, Inc. (Nasdaq: STEM) announced today that Armin Curt, M.D., study principal investigator, presented an interim update on the Phase I/II trial in spinal cord injury at the Annual Meeting of the American Spinal Injury Association in San Antonio, Texas. Interim analysis of clinical data to date has shown that the significant post-transplant gains in sensory function first reported in two patients have now been observed in two additional patients.
The presentation included the first data on AIS B subjects to be transplanted in the Phase I/II chronic... More
StemCells (STEM) Posts Q1 Results and Data Is Coming, Maxim Group Says
May 15, 2014 7:39 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $2.50 price target on StemCells (NASDAQ: STEM) following first quarter results and an overall update on the current clinical programs with a focus on PI/II spine and AMD trials.
The analyst... More
